03839.HK
Chia Tai Enterprises International Limited
HKSE · Healthcare · Drug Manufacturers - Specialty & Generic · HK
HKD 8.69
−1.03%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 424.0M | 536.7M | 307.7M | 174.0M | 159.2M |
| Cost of Revenue | 353.6M | 459.2M | 258.8M | 140.2M | 120.0M |
| Gross Profit | 70.4M | 77.6M | 48.9M | 30.2M | 39.2M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 40.4M | 38.6M | 37.8M | 38.3M | 34.3M |
| General & Admin Expense | 23.8M | 23.5M | 24.4M | 22.2M | 21.2M |
| Selling & Marketing Expense | 16.6M | 15.1M | 13.3M | 12.5M | 13.1M |
| Other Expenses | — | — | — | (3.6M) | — |
| Total Operating Expenses | 40.4M | 38.6M | 37.8M | 34.7M | 34.3M |
| Cost and Expenses | 394.0M | 497.8M | 296.6M | 178.5M | 154.4M |
| Operating Income (EBIT) | 30.0M | 38.9M | 11.2M | (4.5M) | 4.9M |
| Non-Operating | |||||
| Interest Income | — | 926.4K | 1.4M | 1.1M | 368.0K |
| Interest Expense | 1.2M | 1.7M | 2.2M | 2.0M | 994.0K |
| Net Interest Income | (1.2M) | (770.1K) | (829.0K) | (805.0K) | (626.0K) |
| Other Non-Op Income/Expense | 3.6M | 5.4M | 4.9M | 7.5M | (7.6M) |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 33.5M | 44.3M | 16.1M | 2.9M | (2.7M) |
| Income Tax Expense | 6.4M | 7.3M | 2.1M | 1.1M | 1.5M |
| Bottom Line | |||||
| Net Income | 24.4M | 32.1M | 11.2M | 2.6M | (6.7M) |
| Earnings from Cont. Ops | 27.1M | 37.0M | 13.9M | 1.9M | (4.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 24.4M | 32.1M | 11.2M | 2.6M | (6.7M) |
| Per Share | |||||
| Basic EPS | HK$0.10 | HK$0.13 | HK$0.04 | HK$0.01 | (HK$0.03) |
| Diluted EPS | HK$0.10 | HK$0.13 | HK$0.04 | HK$0.01 | (HK$0.03) |
| Revenue Per Share | HK$1.76 | HK$2.12 | HK$1.21 | HK$0.69 | HK$0.63 |
| Shares | |||||
| Basic Shares Outstanding | 240.6M | 253.3M | 253.3M | 253.3M | 253.3M |
| Diluted Shares Outstanding | 240.6M | 253.3M | 253.3M | 253.3M | 253.3M |
| Profitability Metrics | |||||
| EBITDA | 34.7M | 48.3M | 17.5M | 11.3M | 5.2M |
| D&A | 9.0M | 9.3M | 6.3M | 6.4M | 6.9M |
| EBIT | 30.0M | 38.9M | 11.2M | 4.9M | (1.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026